SO-27 Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142
Thierry André, Sara Lonardi, Ka Yeung Mark Wong, Heinz‐Josef Lenz, Fabio Gelsomino, Massimo Aglietta, Michael A. Morse, Eric Van Cutsem, Ray McDermott, Andrew Hill, Michael B. Sawyer, Alain Hendlisz, Bart Neyns, Sandzhar Abdullaev, Arteid Memaj, Ming Lei, Scott Kopetz, Michael J. Overman
Topics & Concepts
MedicineIpilimumabNivolumabKRASInternal medicineMicrosatellite instabilityClinical endpointColorectal cancerCancerOncologyResponse Evaluation Criteria in Solid TumorsPhases of clinical researchSurgeryGastroenterologyClinical trialImmunotherapyAlleleBiochemistryGeneChemistryMicrosatelliteGenetic factors in colorectal cancerCancer Immunotherapy and BiomarkersColorectal Cancer Treatments and Studies